# AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial

> **Open Intelligence Dossier** · First detected: 2026-10-19 19:20 UTC · Category: Business

## Executive Summary
AbbVie presents phase 2 trial data for its next-generation Crohn's disease therapy, ABBV-466.

## Intelligence Brief
Recent reporting outlines significant developments regarding pharmaceutical treatments for Crohn&amp;#039;s disease and inflammatory bowel disease, centered on announcements from AbbVie. According to coverage from outlets including Fierce Biotech, Investing News Network, and grafa.com, data has been presented for ABBV-466, described as a novel dual-targeting therapy. The phase 2 trial results indicate that this next-generation combination treatment achieved higher endoscopic remission rates compared to either anti-IL-23 or anti-beta-7 monotherapy in patients suffering from moderate to severe Crohn&amp;#039;s disease. Additional specifics from grafa.com point to an achieved remission figure of forty and a half percent within the trial parameters. Simultaneously, coverage from Yahoo Finance and MedPage Today highlights concurrent presentations at the UEGW 2026 event.


These reports detail long-term clinical and endoscopic outcomes across inflammatory bowel disease for established medications Skyrizi, known generically as risankizumab, and Rinvoq, known as upadacitinib. MedPage Today specifically emphasizes the outcomes of subcutaneous risankizumab induction for Crohn&amp;#039;s disease patients. The concurrent rollout of these data sets positions the newer experimental compound alongside the company&amp;#039;s existing portfolio of targeted biological therapies in medical discourse. Context provided by the aggregated headlines situates these disclosures within ongoing clinical evaluations for inflammatory bowel disease management. The medical community is presented with comparative phase 2 metrics evaluating dual-targeting approaches against established single-target monotherapies.


While the coverage outlines the relative efficacy metrics reported at the presentation events, broader contextual implications regarding regulatory timelines or commercialization schedules are not currently established in the source material. Future developments will depend on subsequent trial phases and regulatory review processes, though current coverage does not yet specify dates for subsequent clinical milestones. Observers and stakeholders will monitor how these phase two findings for ABBV-466 translate into advanced-stage clinical development, alongside continued real-world data collection for Skyrizi and Rinvoq across inflammatory bowel disease indications. Readers must look to future announcements for definitive timelines regarding regulatory submissions or expanded clinical trial readouts.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Investing News Network | AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-?4?7 Monotherapy in Moderate to Severe Crohn's Disease | [Source Link](https://news.google.com/rss/articles/CBMixwJBVV95cUxQU2swRzZiNnd5dGcxM0pHQkQ0LUV4NnREZ3REb0xfMWdqWnJKY2hRSU5lMlpuMEZmYWdkdzFXY3EzQmR6QzI5NnZIcWo2MkNLa0hWWEo2MlNLUVRvUmdGeGI5a3pDVFdqOWUwdVdhRnFBRUJ3UE9oNHF5WWp1NXozRWpsVlltYVRsNzIybTVXU2RDdEtCaU5xRTJmSERTRGt2WTU3ZDY1Ujc4TlpMQ3VZZHJ4OW5YNGJTUnIxTFd2YVFZMVh1ZFZNRVViSVVxbDFBOVBUZTkxaUtqUmNiY3I4cGFoUlZ2Si1jdGU3ZEE2dUFGMXE2bEw5bWJPb184U0hES1dXckI0YXEzMF9Oa21CVkJTNkJuN01VMlZzSG9HdG5oWDRGMXBqZ1dOZy0yenNibUNYaHpxNVlhcmZvNzNwbFVFUEFsbFk?oc=5) |
| Yahoo Finance | SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZWdwOTZlYS13c3B0TTlfb09IbmZWZ3FWNVNpRktLV1JuYVVlTEMtTEY0YXZ3QlV3eWd4TFZOOGFMS2xzNC1mOEdRUGxMQm9HUk9weXM5Mld2UFRBeWRfZDRWRFVMSWVZZUFuZTZXdlhYSllqaXgwVDhCd1YteUstRk5wb192RVRscFRIZzQ1ZUtjZHJ6T0I3VFZDMi1WMWtwdGtVem1ucDlXZw?oc=5) |
| MedPage Today | Subcutaneous Risankizumab Induction Improved Outcomes in Crohn's Disease | [Source Link](https://news.google.com/rss/articles/CBMiZkFVX3lxTE1iOEtjQmlEbDNUaEhhZTVLbFM0Mk42TzNucDl5aC1tOG1Qa0JYdHk5V2ZPMVd1cFpFYlZJak1EbW5TQjhMZkw1LV9KR20xRTFETGk2RVhEYXhXRUYzNEJGWGcwMkp4Zw?oc=5) |
| grafa.com | AbbVie ABBV-466 Achieves 40.5% Crohn's Remission | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxNTG14Rk5zeGhEOEl6V2V1Sy12cThCUGFZQkt1cWo1T1QySWNZX2YtWHR2RGpWOENWSW5XTzdNbWhCTzNNUnpfa2tBZU9QbkdiTm9CRk9SVzJucDhkWEwxRWZGUlV5U2gwMGF6MGQyaEl3bEZMOC00LXBkRk9KOVFRb3lLLWE5WUM2VjYtTDFuanI1dU1ZMFE?oc=5) |
| Fierce Biotech | AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxNLVhXd3hYZ3JON05ENHJzdFpKdlI2V1dMUmhpU3lKTnhiMXBZYng2LS1MVWtMVzFRbTBwU1dYS1dfLWNYczhVRFJ4blhkcFRTMFg3bWZnczM1dWI3VlphVHRINWxzbE55T2lFM0tDaVhQYml3MWpJUnM0amI3MTlIdTlaWk8wUGtWdHl5WG5ublFPVGI3UnJnMG1pbWlHYTRsZ09z?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-10-19/abbvie-s-next-gen-crohn-s-disease-combo-beats-skyrizi-in-phase-2-trial*
